We next tested the therapeutic potential of HITI in the liver of a mouse model of MPS VI, a severe lysosomal storage disease, and show that newborn MPS VI mice treated with AAV-HITI have stable serum ARSB levels up to 12 months after treatment, as well as normalized liver ARSB activity. This evidence concerns the gene ARSB and mucopolysaccharidosis type 6.